Atlas of Genetics and Cytogenetics in Oncology and Haematology
inv(16)(p13q22) in treatment related leukemia
| Identity |
| Note | This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002. |
 | |
| inv(16)(p13q22) G-banding - Courtesy Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services | |
| Clinics and Pathology |
| Disease | Treatment related myelodysplasia (t-MDS) or acute non lymphocytic leukaemias (t-ANLL) |
| Note | The study included 48 cases; t-MDS without progression to ANLL accounted for 8%, t-MDS with progression to ANLL for 13% and t-ANLL for the remaining 79% the ANLL subtype was M4eo in 83%, M2 in 14%; no case of acute lymphoblastic leukaemia |
| Epidemiology | inv(16)(p13q22) was found in 9% of t-MDS/t-ANLL; sex ratio: 18M/30F |
| Clinics | Age at diagnosis of the primary disease 43 yrs (range 6-75); age at diagnosis of the t-MDS/t-ANLL: 48 yrs (range 13-77). Median interval was short: 22 mths (range: 8-533). Primary disease was a solid tumor in 71% of cases (in particular breast cancer, sarcoma, cancer of the ovary) and a hematologic malignancy in 27%, treatment was radiotherapy (21%, a relatively high proportion compared to other groups), chemotherapy (29%), or both (50%). Treatment included topoisomerase II inhibitors in 60% of cases and alkylating agents in 63%. |
| Prognosis | Patients under 55 yrs of age had better outcome. Median survival was 29 mths, with 45% of patients surviving at 5 yrs, the best survival among subgroups of treatment related leukemias with a balanced chromosome aberration (patients with 11q23 rearrangement, 3q21q26 rearrangement, 12p13 rearrangement, t(9;22), t(8;16), or a 21q22 rearangement)). Patients with t(15;17) had similar median survival, but less long term survivors. |
| Cytogenetics |
| Additional anomalies | The inv(16) was found solely in 46% of cases; additional anomalies were: +8 in 17% , +21 in 13%, +22 in 8%, -7/del(7q) in 8%, +13 in 6%, or -5/del(5q). |
| Result of the chromosomal anomaly |
| Description | 5'CBFB -3¹ MYH11 |
| External links |
| Other database | inv(16)(p13q22) in treatment related leukemia | Mitelman database (CGAP - NCBI) |
| Bibliography |
| Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. |
| Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J |
| Genes, chromosomes & cancer. 2002 ; 33 (4) : 395-400. |
| PMID 11921273 |
| Contributor(s) |
| Written | 10-2003 | Jean-Loup Huret |
| Citation |
| This paper should be referenced as such : |
| Huret JL . inv(16)(p13q22) in treatment related leukemia. Atlas Genet Cytogenet Oncol Haematol. October 2003 . URL : http://AtlasGeneticsOncology.org/Anomalies/inv16p13q22TreatRelID1297.html |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Sat Feb 6 15:45:15 CET 2010 |
For comments and suggestions or contributions, please contact us